Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Therapeutic or Preventive Procedure > Apheresis

Apheresis

Apheresis is a medical procedure where blood is separated into its components, and specific components are selectively removed or retained.
This process is used to treat various medical conditions, such as autoimmune disorders, blood cancers, and other conditions requiring the removal or exchange of specific blood components.
PubCompare.ai helps researchers optimize their apheresis research by identifying the most reliable protocols from literature, preprints, and patents, leveraging AI-driven comparisons to enhance reproducibility and accuracy.
Streamline your apheresis research with PubCompare.ai's powerful featurtes.

Most cited protocols related to «Apheresis»

1
Thermosensitive Liposomal Doxorubicin Release
Cited 12 times
Measurements were performed in a commercially available LTSL formulation (Thermodox®, Celsion, Columbia, MD). The fluorescence intensity of a solution of DOX-loaded liposomes is low due to DOX’s self-quenching. Upon DOX release from a liposome, the fluorescence intensity of a liposome solution is increased. DOX-release experiments were performed by adding a liposome suspension (10 μL, 2 mg/mL DOX) to 750 μL human plasma (plasma collected with apheresis, whole blood treated with 1:12 ACD – anticoagulant citrate dextrose solution A). Prior to adding liposomes, plasma was equilibrated to a predetermined temperature (25°, 37°–47°C) in 1 mL total volume cuvette (1 cm path length) for at least 5 min. The change in fluorescence intensity due to DOX release from the liposomes was monitored with a Cary Eclipse spectrofluorometer equipped with a Peltier temperature controller and Eclipse Kinetic Software (Varian, CA) for 60 s at various temperatures. 15 μL of 25% (wt/wt) Triton X-100 was added at the end of the 60 s to lyse the liposomes and induce maximum release of DOX from the liposome. Excitation and emission wave-lengths were set at 498 nm (5 nm slit width) and 593 nm (10 nm slit width), respectively. The amount of DOX released after time t was calculated according to Equation 1:
%ReleaseofDOX=100[It−IoImax−Io] where It represents the intensity at time t. Io is the fluorescence intensity at 25°C and Imax is the intensity after the addition of Triton. The experiment was repeated three separate times in different plasma samples and data are reported as the mean (n = 3).
GASSELHUBER A., DREHER M.R., NEGUSSIE A., WOOD B.J., RATTAY F, & HAEMMERICH D. (2010). Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 26(5), 499-513.
Publication 2010
acid citrate dextrose Anticoagulants Apheresis BLOOD Citrates Fluorescence Glucose Homo sapiens Kinetics Liposomes Plasma Triton X-100
2
Isolation and Culture of Mesenchymal Stromal Cells
Cited 9 times
Mesenchymal stromal cells were isolated from the bone marrow of six donors (ranging from 54 to 82 years) after orthopedic hip replacement surgery. All samples were taken after informed and written consent of all participants. The study and the experimental design were approved of the local ethics committees (donor 1–4: RWTH Aachen; EK300/13; donor 5–6: University of Würzburg OBELICS 100/14) and all methods were performed in accordance with the relevant guidelines and regulations. Cells were isolated as described before15 (link). In brief, cells were flushed from the bone and cultured in parallel in basal medium with either 10% FCS or 10% HPL in a seeding density of 10,000 cells/cm2. Basal medium consisted of Dulbecco’s Modified Eagle Medium (DMEM, 1 g/L glucose; PAA, Pasching, Austria) with 1% penicillin/streptomycin (PAA) and 1% L-glutamine. Based on an initial screen of 11 FCS batches (Supplementary Figure S1) all experiments were performed with FCS from Bio&Sell (Lot number: 211507.5 A; Feucht, Germany) to exclude variation. HPL was generated as described previously6 (link), 28 (link). In brief, platelet units were generated by apheresis using the Trima Accel Collection System (CaridianBCT, Garching, Germany), aliquots of 45 mL were twice frozen at −80 °C and re-thawed at 37 °C, and then centrifuged at 2,600 × g for 30 minutes. The supernatant was filtered through 0.2 µm GD/X PVDF filters (Whatman, Dassel, Germany) and stored at −80 °C until use. To reduce variation we used HPL-pools consisting of at least 5 lysates. Coagulation was prevented by 0.61 IU unfractionated heparin (UFH; Ratiopharm, Ulm, Germany).
Fernandez-Rebollo E., Mentrup B., Ebert R., Franzen J., Abagnale G., Sieben T., Ostrowska A., Hoffmann P., Roux P.F., Rath B., Goodhardt M., Lemaitre J.M., Bischof O., Jakob F, & Wagner W. (2017). Human Platelet Lysate versus Fetal Calf Serum: These Supplements Do Not Select for Different Mesenchymal Stromal Cells. Scientific Reports, 7, 5132.
Publication 2017
Apheresis Blood Platelets Bone Marrow Bones Cells Coagulation, Blood Donors Eagle Freezing Glucose Glutamine Heparin Mesenchymal Stromal Cells Orthopedic Surgical Procedures Penicillins polyvinylidene fluoride Regional Ethics Committees Replacement Arthroplasties, Hip SELL protein, human Streptomycin Tissue Donors
3
Allogeneic Hematopoietic Stem Cell Transplantation
Cited 7 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2011
Apheresis Body Weight Cells Cytoreductive Surgery Disease Progression Grafts Patients Stem Cells T-Lymphocyte Tissue Donors Transplantation Treatment Protocols
4
Murine vs. Human T-Reg Suppression Assays
Cited 7 times
An important difference between murine and human in vitro Treg suppression assays is the source of cells. Murine Tconv and Treg are predominantly purified from spleens and lymph nodes on the basis of CD25 expression. However, human Tconv and Treg can be isolated from peripheral blood (from PBMCs or apheresis rings, depending upon availability) or umbilical cord blood. In human peripheral blood, suppressive capacity is not associated with all CD25+ cells, as it is in the mouse, but instead with the brightest subset of CD25+ cells (termed CD25bright). Another complication with using peripheral blood Tconv and Tregs is that unlike in the mouse, Foxp3 can be expressed in both Treg and activated Tconv, making classification and purity analysis difficult. For this reason, a number of additional cell surface markers have been used to help purify peripheral blood Tconv and Treg, with relative degrees of success. For detailed information regarding purification, subsets of human Tregs, and alternative cell surface markers for identification of Tregs, see refs. (15 (link)-18 (link)). An alternative source of human Tconv and Treg is umbilical cord blood. Unlike peripheral T cells, cord blood Tconv have not encountered any peripheral antigen; therefore, CD25 expression is a much better marker for Tregs. In addition, both Foxp3 expression and suppressive capacity are exclusively within the CD25+ population. The complications with using umbilical cord blood samples are (1 (link)) access to samples (2 (link)) both Tconv and Treg are antigen inexperienced as they have never entered peripheral circulation. For this reason, additional manipulation is required; IL-2 supplementation to achieve strong proliferation of Tconv and pre-activation for maximum suppressive capacity of Tregs.
Collison L.W, & Vignali D.A. (2011). In Vitro Treg Suppression Assays. Methods in molecular biology (Clifton, N.J.), 707, 21-37.
Publication 2011
Antigens Apheresis Biological Assay BLOOD Cells Homo sapiens IL2RA protein, human Mus Nodes, Lymph Regulatory T-Lymphocytes T-Lymphocyte Umbilical Cord Blood
5
Isolation and Activation of Primary Human T Cells
Cited 6 times
Primary human T cells were isolated from healthy human donors either from fresh whole blood, residuals from leukoreduction chambers after Trima Apheresis (Blood Centers of the Pacific), or leukapheresis products (StemCell). Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples by Ficoll centrifugation using SepMate tubes (STEMCELL, per manufacturer’s instructions). T cells were isolated from PBMCs from all cell sources by magnetic negative selection using an EasySep Human T Cell Isolation Kit (STEMCELL, per manufacturer’s instructions). Unless otherwise noted, isolated T cells were stimulated as described below and used directly (fresh). When frozen cells were used, previously isolated T cells that had been frozen in Bambanker freezing medium (Bulldog Bio) per manufacturer’s instructions were thawed, cultured in media without stimulation for 1 day, and then stimulated and handled as described for freshly isolated samples. Fresh blood was taken from healthy human donors under a protocol approved by the UCSF Committee on Human Research (CHR #13-11950). Patient samples used for gene editing were obtained under a protocol approved by the Yale Human Investigation Committee (HIC). Additional leukapheresis products from healthy donors were collected either under UCLA Institutional Review Board (IRB) approval #10-001598 or purchased from AllCells, LLC. All patients and healthy donors provided informed consent.
Roth T.L., Puig-Saus C., Yu R., Shifrut E., Carnevale J., Li P.J., Hiatt J., Saco J., Krystofinski P., Li H., Tobin V., Nguyen D.N., Lee M.R., Putnam A.L., Ferris A.L., Chen J.W., Schickel J.N., Pellerin L., Carmody D., Alkorta-Aranburu G., Gaudio D.D., Matsumoto H., Morell M., Mao Y., Cho M., Quadros R.M., Gurumurthy C.B., Smith B., Haugwitz M., Hughes S.H., Weissman J.S., Schumann K., Esensten J.H., May A.P., Ashworth A., Kupfer G.M., Greeley S.A., Bacchetta R., Meffre E., Roncarolo M.G., Romberg N., Herold K.C., Ribas A., Leonetti M.D, & Marson A. (2018). Reprogramming human T cell function and specificity with non-viral genome targeting. Nature, 559(7714), 405-409.
Publication 2018
Apheresis BLOOD Cells Cell Separation Centrifugation Culture Media Donors Ethics Committees, Research Ficoll Homo sapiens Leukapheresis Patients PBMC Peripheral Blood Mononuclear Cells Stem Cells T-Lymphocyte

Most recents protocols related to «Apheresis»

1
Maintenance Therapy After Anti-CD19 CAR T-Cells
Approximately 60 days after anti-CD19-CAR T-cell infusion, when the adverse
events (AEs) and the subsequent aGVHD disappeared, patients who obtained CR or
CR with incomplete count recovery (Cri) and had previously preserved frozen stem
cells, received DSI (DSI group) as maintenance therapy. The other patients who
reached CR/CRi received DLI (DLI group) as maintenance therapy. The cells in DLI
therapy were not previously frozen, but were collected by hemapheresis without
mobilization by granulocyte colony stimulating factor (G-CSF) in every DLI
maintenance therapy. All DSI/DLI was the same donor used for the original
hematopoietic stem cell transplant. The interval time between the two DSI/DLI
therapies was generally 1 month. If the patients develop severe aGVHD, DSI/DLI
maintenance therapy would be discontinued. Moreover, one patient who reached
CR/Cri received a second allo-HSCT following DLI therapy (Fig. 1). One patient who did not reach
CR/CRi after anti-CD19-CAR T-cell therapy received DSI as a salvage therapy. Two
other patients who did not reach CR/Cri died because of disease progression
within a short time.
Li Q., Lyu C., Liu M., Wang J., Mou N., Jiang E., Zhang R, & Deng Q. (2023). Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. Cell Transplantation, 32, 09636897231158155.
Publication 2023
Apheresis Freezing Granulocyte Colony-Stimulating Factor Patients Salvage Therapy Therapeutics Therapies, CAR T-Cell Tissue Donors Transplantations, Stem Cell
2
Anti-CD19 CAR T-cell Therapy for B-ALL
All the donors of the 22 patients with B-ALL provided their peripheral blood
mononuclear cells (PBMCs) by hemapheresis for this anti-CD19-CAR T-cell therapy.
CD3+ T-cells were isolated by Ficoll density gradient centrifugation and elected
by CD3 microbeads (Miltenyi Biotec, Inc., Cambridge, MA, USA), then stimulated
by anti-CD3/anti-CD28 mAb-coated Human T-Expander beads (Cat. no. 11141D; Thermo
Fisher Scientific, Inc., Waltham, MA, USA) and cultured in T-cell medium X-Vivo
15 (Lonza Group, Ltd., Basel, Switzerland) supplemented with 250 IU/mL
interleukin-2 (IL-2; Proluekin; Novartis International AG, Basel, Switzerland).
All CD3+ T-cells (3 × 106) of the 22 donors were transduced with
lentiviral vector encoding humanized CD19 CAR constructs (10 µg,
lenti-CD19-2rd-CAR, 4-1BB costimulatory molecule; Shanghai Genbase Biotechnology
Co., Ltd. Shanghai, China) and cultured in media containing recombinant human
IL-2 (250 IU/mL). On the 12th to 14th day of cultivation, transduction
efficiencies of anti-CD19-CAR were analyzed using FCM (BD Biosciences, San Jose,
CA, USA). Lymphodepletion chemotherapy comprised fludarabine (30
mg/m2) and cyclophosphamide (400 mg/m2) from day 4 to
day 2. All donor-derived anti-CD19-CAR T-cells were infused on day 0 (1 ×
106 cells/kg) in patients with B-ALL.
Li Q., Lyu C., Liu M., Wang J., Mou N., Jiang E., Zhang R, & Deng Q. (2023). Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant. Cell Transplantation, 32, 09636897231158155.
Publication 2023
Apheresis Burkitt Leukemia Cells Centrifugation, Density Gradient Cloning Vectors Culture Media Cyclophosphamide Donors Ficoll fludarabine Homo sapiens Microspheres Muromonab-CD3 Patients Pharmacotherapy T-Lymphocyte Therapies, CAR T-Cell Thomsen-Friedenreich antibodies Tissue Donors
3
Isolation and Activation of Primary Human CD4+ T Cells
Primary human CD4+ T cells from healthy donors were isolated from leukoreduction chambers after Trima apheresis (STEMCELL Technologies). PBMCs were isolated by Ficoll centrifugation. Bulk CD4+ T cells were subsequently isolated from PBMCs by magnetic negative selection using an EasySep Human CD4+ T cell isolation kit (STEMCELL Technologies; per the manufacturer’s instructions). Isolated CD4+ T cells were suspended in RPMI 1640 (Sigma-Aldrich) supplemented with 5 mM Hepes (Corning), penicillin-streptomycin (50 mg/ml; Corning), 5 mM sodium pyruvate (Corning), and 10% FBS (Gibco). Media were supplemented with interleukin-2 (IL-2; 20 IU/ml; Miltenyi) immediately before use. For activation, bulk CD4+ T cells were immediately plated on anti-CD3–coated plates [coated for 2 hours at 37°C with anti-CD3 (20 mg/ml) (UCHT1; Tonbo Biosciences)] in the presence of soluble anti-CD28 (5 mg/ml; CD28.2; Tonbo Biosciences). Cells were stimulated for 72 hours at 37°C and 5% CO2 before treatment with iPAF1C.
Soliman S.H., Cisneros W.J., Iwanaszko M., Aoi Y., Ganesan S., Walter M., Zeidner J.M., Mishra R.K., Kim E.Y., Wolinsky S.M., Hultquist J.F, & Shilatifard A. (2023). Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C. Science Advances, 9(10), eadf2468.
Publication 2023
Apheresis CD4 Positive T Lymphocytes Cells Centrifugation Dietary Fiber Donors Ficoll HEPES Homo sapiens Muromonab-CD3 Penicillins Pyruvate Sodium Stem Cells Streptomycin
4
Autologous Hematopoietic Stem Cell Transplantation for MM and Lymphoma
50 MM and lymphoma candidates for AHSCT in the department of bone marrow transplantation center, Taleghani hospital (Tehran, Iran) were selected between September 2021 and August 2022. All protocols and blood sampling were conducted after filling out the informed consent form by patients and confirmation in ethics committee of Hamadan university of medical sciences (Ethic code No: IR.UMSHA.REC.1400.541). Mobilization was done by granulocyte colony-stimulating factor (G-CSF) administration in a steady state. After mobilization and leukocyte count reaches to the appropriate number, for HSCs collection from peripheral blood, Spectra Optia Apheresis System was applied. Lomustine, Etoposide, Cytarabine, Melphalan (CEAM) or Carmustine, Etoposide, Cytarabine, Melphalan (BEAM), and Melphalan/Velcade were conditioning regimens for lymphoma and MM patients, respectively. Patients’ available data was collected from diagnosis to transplantation phase and almost 90 weeks (as the median) follow-up from medical records and new laboratory tests that were done on the patients. 2–4 milliliters of peripheral blood samples were obtained in EDTA containing tube at two times. The first sample was 1–2 days before mobilization and the second sample was 1–2 days after conditioning and before HSCs re-infusion (post conditioning sample).
Rafiee M., Amiri F., Mohammadi M.H, & Hajifathali A. (2023). MicroRNA-125b as a valuable predictive marker for outcome after autologous hematopoietic stem cell transplantation. BMC Cancer, 23, 202.
Publication 2023
Apheresis BLOOD Bone Marrow Transplantation Carmustine Cytarabine Diagnosis Edetic Acid Ethics Committees Etoposide Granulocyte Colony-Stimulating Factor Leukocyte Count Lomustine Lymphoma Melphalan Patients Stem Cells, Hematopoietic Transplantation Treatment Protocols Velcade
5
Satralizumab Monotherapy for AQP4-IgG+ NMOSD
Participants will be treated with satralizumab 120 mg as monotherapy via subcutaneous injection using a pre-filled syringe at Weeks 0, 2, 4, and then every 4 weeks until the last administration at Week 92. This is consistent with the licensed dosing regimen of satralizumab in AQP4-IgG+ NMOSD (9 , 10 ). The first dose of satralizumab will be administered by the site staff at Week 0. The second dose will be self-administered by participants (or their caregivers) under the supervision of a designated study staff member at the study site at Week 2. If the treating physician is satisfied that the participant (or their caregiver) can perform the injection, all subsequent doses may be administered at home. A telephone interview the working day after each satralizumab dose will confirm compliance, and evaluate any changes in health status (e.g., new or worsening neurological symptoms, or any possible AEs).
Rescue therapy for clinical relapses and pain medications are both permitted during the study. Rescue therapies include pulse intravenous corticosteroids, oral corticosteroids for tapering, intravenous immunoglobulin, and/or apheresis (including plasma exchange [PLEX] and plasmapheresis). Pain medications include, but are not limited to, pregabalin, gabapentin, carbamazepine, clonazepam, duloxetine, and tramadol/acetaminophen. Combination treatment with immunosuppressive therapies (e.g., azathioprine, cyclosporine, methotrexate, mycophenolate mofetil, tacrolimus) is not permitted, even if a relapse occurs.
Bennett J.L., Fujihara K., Kim H.J., Marignier R., O'Connor K.C., Sergott R.C., Traboulsee A., Wiendl H., Wuerfel J., Zamvil S.S., Anania V.G., Buffels R., Künzel T., Lekkerkerker A.N., Lennon-Chrimes S, & Pittock S.J. (2023). SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. Frontiers in Neurology, 14, 1114667.
Publication 2023
Acetaminophen Adrenal Cortex Hormones Apheresis Azathioprine Carbamazepine Clonazepam Combined Modality Therapy Cyclosporine Duloxetine Gabapentin Immunosuppressive Agents Intravenous Immunoglobulins Methotrexate Mycophenolate Mofetil Neurologic Symptoms Pain Pharmaceutical Preparations Physicians Plasmapheresis Pregabalin Pulse Rate Relapse satralizumab Subcutaneous Injections Supervision Syringes Tacrolimus Tramadol Treatment Protocols

Top products related to «Apheresis»

1
Ficoll paque by GE Healthcare
Sourced in Sweden, United States, United Kingdom, Germany, Canada, Belgium, Italy, Australia, Austria, France, Japan, Singapore, Denmark
Ficoll-Paque is a density gradient medium used for the isolation and purification of cells, such as mononuclear cells, from whole blood or other biological samples. It is designed to separate different cell types based on their density differences during centrifugation.
2
Rpmi 1640 by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.
3
Ficoll paque plus by GE Healthcare
Sourced in Sweden, United States, United Kingdom, Germany, Canada, Japan, Italy, China, France, Australia, Belgium, Austria, Spain, Switzerland, Norway, New Zealand, Denmark, Finland, Georgia
Ficoll-Paque PLUS is a sterile, ready-to-use medium for the isolation of mononuclear cells from blood or bone marrow by density gradient centrifugation. It is a polysucrose and sodium diatrizoate solution with a density of 1.077 g/mL.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
L glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.
6
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
7
Spectra optia by Terumo BCT
Sourced in United States, Japan
The Spectra Optia is a cell separation system designed for therapeutic cell collection and processing. It is capable of performing procedures such as platelet, plasma, or mononuclear cell collection and exchange transfusion. The device utilizes centrifugation technology to separate and collect specific blood components.
8
Human ab serum by Merck Group
Sourced in United States, Germany, United Kingdom, Belgium, Switzerland, Japan, Spain
Human AB serum is a laboratory reagent that consists of the liquid portion of human blood, specifically from individuals with the AB blood type. It is obtained by separating the cellular components from the blood, leaving behind the serum. This serum can be used as a supplement in cell culture media to provide essential nutrients and growth factors for the cultivation of various cell types in a laboratory setting.
9
X vivo 15 by Lonza
Sourced in United States, Switzerland, United Kingdom, Belgium, Germany, China, Denmark
X-VIVO 15 is a serum-free, protein-free, and chemically defined medium designed for the in vitro culture of a variety of cell types, including hematopoietic cells, epithelial cells, and fibroblasts. The medium is optimized to support cell growth and proliferation while maintaining cell function and viability.
10
Clinimacs by Miltenyi Biotec
Sourced in Germany, United Kingdom, United States
The CliniMACS system is a laboratory equipment designed for the magnetic separation and enrichment of specific cell populations from biological samples. It utilizes antibody-coated magnetic beads to isolate target cells, enabling their further analysis or potential therapeutic applications. The system provides a controlled and automated environment for cell separation, ensuring consistent and reliable results.

More about "Apheresis"

Apheresis is a specialized medical procedure where blood is separated into its individual components, allowing for the selective removal or retention of specific blood elements.
This process is commonly used to treat various medical conditions, such as autoimmune disorders, blood cancers, and other conditions that require the adjustment or exchange of particular blood components.
PubCompare.ai is a powerful tool that helps researchers optimize their apheresis research by identifying the most reliable and effective protocols from the available literature, preprints, and patents.
By leveraging AI-driven comparisons, the tool can enhance the reproducibility and accuracy of apheresis research, streamlining the process and enabling researchers to make more informed decisions.
In the context of apheresis research, related terms and concepts may include Ficoll-Paque, a density gradient medium often used for the isolation and purification of cells, such as peripheral blood mononuclear cells (PBMCs).
RPMI 1640 is a commonly used cell culture medium that provides the necessary nutrients for cell growth and maintenance.
Ficoll-Paque PLUS is a refined version of Ficoll-Paque, optimized for improved cell separation and recovery.
Furthermore, fetal bovine serum (FBS) and human AB serum are often used as supplements in cell culture media to provide additional growth factors and nutrients.
L-glutamine is an essential amino acid that is commonly added to cell culture media to support cell proliferation and metabolism.
Penicillin and streptomycin are antibiotics used to prevent bacterial contamination in cell culture experiments.
The Spectra Optia is a specialized apheresis device that enables the selective removal or exchange of specific blood components, while X-VIVO 15 is a serum-free, chemically defined medium often used for the culture and expansion of various cell types, including those derived from apheresis procedures.
The CliniMACS system is another important tool in apheresis research, as it allows for the isolation and purification of specific cell populations, such as T cells or stem cells, from the collected blood components.
By leveraging the insights and capabilities provided by PubCompare.ai and understanding the relevant terms and technologies, researchers can streamline their apheresis research, optimize their protocols, and enhance the reproducibility and accuracy of their findings.